Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIB randomized double-blind placebo-controlled trial of MEDI6570 in post-myocardial infarction patients
2020-000840-75Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI), coronary arteriosclerosis and heart failure (HF) comparing MEDI6570 arm with Placebo arm (2 arms). Primary endpoint: Change in non-calcified plaque volume in the most diseased coronary segment. Started Jul 2020; status: completed.
02
Drugs
golocdacimab
03
Conditions
myocardial infarction (MI)coronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on 2020-000840-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000840-75.